Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status

Dabrafenib plus trametinib is active against metastatic lung cancer with the BRAF V600E mutation. However, the feasibility of dabrafenib plus trametinib for patients with a poor performance status (PS) has not been reported. We report the case of an 80-year-old woman was diagnosed with metastatic la...

Full description

Saved in:
Bibliographic Details
Published in:International cancer conference journal 2022-10, Vol.11 (4), p.266-269
Main Authors: Nakajima, Yuki, Nishijima, Yurie, Niida, Ai, Kiyama, Kouki, Sasaki, Akinori, Fujimoto, Yutaro, Ishizuka, Azusa, Ehara, Jun, Ogita, Shin, Norisue, Yasuhiro
Format: Article
Language:English
Subjects:
Cancer therapies
Case Report
Chemotherapy
Cytotoxicity
Epidermal growth factor
Genotypes
Kinases
Lung cancer
Lung carcinoma
Lung diseases
Lymphatic system
Medicine
Medicine & Public Health
Metastases
Metastasis
Mortality
Mutation
Oncology
Patients
Pneumonia
Surgical Oncology
Tomography
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dabrafenib plus trametinib is active against metastatic lung cancer with the BRAF V600E mutation. However, the feasibility of dabrafenib plus trametinib for patients with a poor performance status (PS) has not been reported. We report the case of an 80-year-old woman was diagnosed with metastatic large-cell lung carcinoma. Her general statuses worsened due to cancer, resulting in a PS of 4. Genotype testing revealed a BRAF V600E mutation. The patient received dabrafenib plus trametinib without significant adverse effects. This report is the first to describe dabrafenib plus trametinib administration for large-cell lung carcinoma in a patient with a poor PS.
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-022-00556-9